|Bid||59.10 x 1400|
|Ask||59.49 x 1800|
|Day's Range||55.50 - 57.77|
|52 Week Range||46.48 - 64.21|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||105.21|
|Forward Dividend & Yield||1.40 (2.41%)|
|Ex-Dividend Date||Aug. 12, 2021|
|1y Target Est||67.68|
A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac's CoronaVac shot, a study has found. The study found that CoronaVac received the strongest boost from a viral vector or RNA shot, including against the Delta and Omicron coronavirus variants, researchers from Brazil and Oxford University said https://www.ox.ac.uk/news/2022-01-24-mixed-vaccine-schedules-offer-strong-booster-responses-after-two-doses-coronavac on Monday. China-based Sinovac's vaccine uses an inactivated version of a coronavirus strain that was isolated from a patient in China.
WILMINGTON, Del., January 24, 2022--Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.
Patients will receive new cancer drugs more quickly following post-Brexit changes to the regulatory oversight of pharmaceuticals.